PerkinElmer (NYSE:PKI) has closed its $1.3 billion deal to buy Euroimmun Medical Laboratory Diagnostics, the scientific instrument-maker reported today.
The acquisition, first announced in June, involves Euroimmun’s 2,400 employees and autoimmune testing solutions. The move helps to expand PerkinElmer’s footprint in autoimmune and allergy diagnostic markets.
Get the full story at our sister site, Drug Delivery Business News.